Johnson & Johnson is a global healthcare conglomerate engaged in the research, development, and manufacture of pharmaceuticals, medical devices, and consumer health products. With a mission to improve health for humanity, J&J operates across three segments: Innovative Medicine, focusing on areas like oncology and immunology; MedTech, providing surgical and orthopedic solutions; and Consumer Health, offering products in baby care, skin health, and oral care. The company emphasizes innovation, sustainability, and global health equity, delivering solutions that impact millions worldwide.
From September 23-26, in Nashville, USA, DePuy Synthes, operating as a key business segment under Johnson & Johnson MedTech, presented integrated trauma fixation systems and digital surgical infrastructure.
Johnson & Johnson has introduced MONARCH QUEST 3, a software update for its MONARCH Platform that adds AI-assisted planning, navigation enhancements, 3D orientation and broader imaging compatibility for bronchoscopic lung nodule procedures.
Johnson & Johnson introduced its robotic bronchoscopy and AI navigation platform at Cleveland Clinic Abu Dhabi to improve early diagnostic accuracy for peripheral lung lesions.
Next-generation software solution includes new AI capabilities to advance the standard of care in total hip arthroplasty (THA) by automating image interpretation, consistently identifying landmarks, and increasing procedural efficiencies.
Johnson & Johnson and Memorial Hermann-Texas Medical Center evaluate the OTTAVA robotic system's performance in multi-quadrant surgical procedures and existing operating room infrastructures.
Johnson & Johnson showcases AI-driven imaging and mapping solutions at HRS 2026 to enhance electrophysiology procedures and treatment of cardiac arrhythmias.
The acquisition adds a clinical-stage prostate cancer therapy and a novel RIPTAC platform aimed at improving precision targeting and overcoming treatment resistance in solid tumors.
Johnson & Johnson terminated its Phase 2b trial for JNJ-5939 after an interim analysis showed the drug failed to meet high-bar efficacy standards for treatment.
Johnson & Johnson MedTech can create high-fidelity digital twins using NVIDIA Omniverse libraries and build applications that simulate how the system may perform in the operating room and inside a patient.
The new tissue-sparing system enables day-one post-op mobility, enhances joint visualization, and supports outpatient surgery as shoulder replacements grow 7.3% annually.